Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 2/2017

01-03-2017 | Original Paper

Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data

Authors: Christine Blome, Matthias Augustin, Hidayet Metin, David Lohrberg

Published in: The European Journal of Health Economics | Issue 2/2017

Login to get access

Abstract

Background

Since 2011, an early benefit assessment (EBA) of new drugs constricts free price setting in Germany. According to the Pharmaceutical Market Restructuring Act (AMNOG), pharmaceutical companies are obliged to demonstrate added benefit of new drugs over comparative treatment. Benefit is usually evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG). The final appraisal is made by the Federal Joint Committee, Germany’s highest-ranking decision body in the health sector, triggering drug prize negotiations between companies and statutory health insurance funds. One of four evaluation criteria is quality of life (QoL). QoL outcomes have, however, only rarely been pivotal in EBAs.

Objective

This study determined methodological requirements for QoL measurement and data presentation in the EBA.

Design

In a qualitative content analysis, documents of all EBAs completed by 2014 were searched for the term QoL. Relevant passages of all EBAs of 2011–2013 were independently extracted and reduced to key content by two researchers. Recurring patterns were identified and verified through comparison with EBAs of 2014.

Results

We identified a range of requirements regarding QoL assessment, analysis, presentation, and interpretation, which go beyond official regulations. Disease-specific questionnaires are preferred and have to be validated according to certain standards and in the respective patient group. Effects must exceed the minimal important difference, which in turn must be validated in compliance with specific requirements. Often, instruments were not accepted as QoL measures, sometimes inconsistently across EBAs. Another frequent reason for non-acceptance of QoL data was that more than 30 % of randomized patients could not be analyzed due to missing data.

Conclusions

Non-compliance with methodological requirements for QoL evidence impairs chances for positive benefit evaluation.
Literature
1.
Franken, M., Le Polain, M., Cleemput, I., Koopmanschap, M.: Similarities and differences between five European drug reimbursement systems. Int. J. Technol. Assess. Health Care 28(4), 349–357 (2012)CrossRefPubMed
2.
Henschke, C., Sundmacher, L., Busse, R.: Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation. Health Policy 109(3), 263–269 (2013)CrossRefPubMed
3.
Fischer, K.E., Stargardt, T.: Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee’s decisions. Med. Decis. Making 34(8), 1030–1047 (2014)CrossRefPubMed
4.
Hörn, H., Nink, K., McGauran, N., Wieseler, B.: Early benefit assessment of new drugs in Germany—results from 2011 to 2012. Health Policy 116(2–3), 147–153 (2014)CrossRefPubMed
5.
Leopold, C., Vogler, S., Mantel-Teeuwisse, A.K., de Joncheere, K., Leufkens, H.G.M., Laing, R.: Differences in external price referencing in Europe: a descriptive overview. Health Policy 104(1), 50–60 (2012)CrossRefPubMed
6.
Ahmed, S., Berzon, R.A., Revicki, D.A., Lenderking, W.R., Moinpour, C.M., Basch, E., Reeve, B.B., Wu, A.W.: The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy. Med. Care 50(12), 1060–1070 (2012)CrossRefPubMed
7.
Kreis, J., Busse, R.: From evidence assessments to coverage decisions? The case example of glinides in Germany. Health Policy 104(1), 27–31 (2012)CrossRefPubMed
8.
9.
Schipper, H., Clinch, J.J., Olweny, C.L.: Quality of life studies: definitions and conceptual issues. In: Spilker, B. (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn, pp. 15–18. Lippincott-Raven, Philadelphia (1996)
10.
Mayring, P.: Qualitative content analysis. In: Flick, U., Kardorff, E.V., Steinke, I. (eds.) A Companion to Qualitative Research, pp. 266–269. Sage Publications, London (2004)
11.
Meyer, T., Karbach, U., Holmberg, C., Güthlin, C., Patzelt, C., Stamer, M.: Qualitative Studien in der Versorgungsforschung—Diskussionspapier, Teil 1: gegenstandsbestimmung [Qualitative research in health services research—discussion paper, part 1: what is the idea?]. Gesundheitswesen 74(8–9), 510–515 (2012)PubMed
12.
13.
The EuroQol Group: EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16(3), 199–208 (1990)CrossRef
14.
Ware, J.E.: The SF-36 health survey. In: Spilker, B. (ed.) Quality of Life and Pharmacoeconomics in Clinical Trials, pp. S337–S346. Lippincott-Raven, Philadelphia (1996)
15.
Aaronson, N.K., Ahmedzai, S., Bergman, B., et al.: The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85(5), 365–376 (1993)CrossRefPubMed
16.
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P., Brannon, J., et al.: The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol. 11(3), 570–579 (1993)PubMed
17.
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., Pienta, K.J.: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50(6), 920–928 (1997)CrossRefPubMed
18.
McKenna, S.P., Doward, L.C., Twiss, J., et al.: International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS). Value Health 13, 946–951 (2010)CrossRefPubMed
19.
Brady, M., Cella, D.F., Mo, F., Bonomi, A.E., Tulsky, D.S., Lloyd, S.R., Deasy, S., Cobleigh, M., Shiomoto, G.: Reliability and validity of the functional assessment of cancer therapy—breast quality-of-life instrument. J. Clin. Oncol. 15, 974–986 (1997)PubMed
20.
Perleth, M., Gibis, B., Göhlen, B.: A short history of health technology assessment in Germany. Int. J. Technol. Assess. Health Care 25(1), 112–119 (2009)CrossRefPubMed
21.
Sattelmeier, J., Prenzler, A., Frank, M.: Das Arzneimittelmarktneuordnungsgesetz (AMNOG) in der Praxis—erste Erfahrungen, Kritikpunkte und Weiterentwicklungsmöglichkeiten. Gesundheitsökonomie & Qualitätsmanagement 18, 213–220 (2013)CrossRef
22.
Klose, K., Witte, J., Kreimeier, S., Greiner, W.: Lebensqualität als Wettbewerbsvorteil in der frühen Nutzenbewertung [Quality of life as advantage in competition within the early benefit assessment]. Public Health Forum 21(4), 14. e1–14. e3 (2013)
23.
Ruof, J., Schwartz, F., Schulenburg, J.-M., Dintsios, C.-M.: Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. Eur. J. Health Econ. 15(6), 577–589 (2014)CrossRefPubMed
Metadata
Title
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
Authors
Christine Blome
Matthias Augustin
Hidayet Metin
David Lohrberg
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 2/2017
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-016-0765-6

Other articles of this Issue 2/2017

The European Journal of Health Economics 2/2017 Go to the issue

Original Paper

A voluntary deductible in health insurance: the more years you opt for it, the lower your premium?

Original Paper

Competition in the Dutch hospital sector: an analysis of health care volume and cost

Original Paper

Assessing asthma severity based on claims data: a systematic review

Original Paper

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment

Original Paper

The cost of frailty in France

Original Paper

How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence